基石药业-B(02616)今日盘中大涨5.05%，引起了市场的广泛关注。
消息面上，基石药业-B发布公告，公司已与配售代理订立配售协议，以每股8.97港元的价格，向不少于六名承配人配售合共1.18亿股股份。假设所有配售股份获悉数认购，配售所得款项净额估计约为10.53亿港元。
公司计划将所得款项净额的90%用于进一步研发“管线2.0”中的资产，特别是CS2009（一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，目前处于II期开发阶段）和CS5001（一种潜在同类最佳的ROR1 ADC）以及其他处于临床前或IND准备阶段的资产。此举被市场视为对公司未来研发能力和增长潜力的积极信号，从而推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.